-
Mashup Score: 3Advancements in Cutting-Edge SABR Therapy for Oligometastatic Kidney Cancer - Shankar Siva - 4 day(s) ago
Alicia Morgans hosts Shankar Siva who sheds light on the innovative use of Stereotactic Ablative Body Radiotherapy (SBRT/SABR) for treating oligometastatic kidney cancer. Dr. Siva outlines the three clinical scenarios where SABR is employed: de novo oligometastatic disease, oligoprogressive disease during systemic therapy, and in certain de novo metastatic settings. He emphasizes the…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 5#LAG-3 With #PD-1 in #kidneycancer #cancerresearch #rcc #cancer - 13 day(s) ago
Katy Beckermann, MD, PhD, and Michael Atkins, MD, discuss the rationale behind targeting LAG-3 as a novel checkpoint inhibitor, highlighting its potential in…
Source: www.youtube.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 13
Drs. Atkins and Beckermann discuss LAG-3 as a novel checkpoint inhibitor combined with anti-PD-1 for kidney cancer.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2Bispecific Antibody Inhibiting PD-1 and CTLA-4 Demonstrates Effectiveness Against Advanced Kidney Cancer in Early Study - Martin Voss - 24 day(s) ago
Pedro Barata engages in a discussion with Martin Voss about volrustomig, a novel PD-1/CTLA-4 bispecific antibody for advanced clear cell RCC. Dr. Voss provides an overview of volrustomig, highlighting its unique ability to inhibit PD-1 and selectively bind CTLA-4 on cells co-expressing both receptors, aiming for targeted action in the tumor microenvironment. He reviews the dose-finding study’s…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Bispecific antibody inhibiting PD-1 and CTLA-4 demonstrates effectiveness against advanced #KidneyCancer in early study. @MVossMD @MSKCancerCenter joins @PBarataMD @caseccc to discuss volrustomig, the effects, abilities, and ongoing trials in this space > https://t.co/6yMV0JMRaN https://t.co/KykU06o6MC
-
-
Mashup Score: 0
An expert explains what patients need to keep in mind and what conversations they should be having with their care teams.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 4
Subcutaneous administration of Opdivo, could increase efficiency and reduce wait times for patients, as one expert explains to CUREĀ®.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 8
Patients with inoperable kidney cancer saw significant results in local control and cancer-specific survival with stereotactic ablative body radiotherapy.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 4Injectable Opdivo āCan Achieve the Same Goalsā as IV Use in RCC - 1 month(s) ago
Subcutaneous administration of Opdivo, could increase efficiency and reduce wait times for patients, as one expert explains to CUREĀ®.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 4Injectable Opdivo āCan Achieve the Same Goalsā as IV Use in RCC - 1 month(s) ago
Subcutaneous administration of Opdivo, could increase efficiency and reduce wait times for patients, as one expert explains to CUREĀ®.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 3Possible Treatment Identified for Rare Kidney Cancer Subtype - 1 month(s) ago
Researchers have determined distinguishing characteristics of TFE3-rearranged renal cell carcinoma.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
Advancements in cutting-edge SABR therapy for oligometastatic #KidneyCancer. @_ShankarSiva @PeterMacCC joins @CaPsurvivorship @DanaFarber to discuss the innovative use of this therapy and its effectiveness in achieving local control > https://t.co/Cs0mpCOEyV https://t.co/TL8aRajvZl